# Cannabinoids as promising anti-tumor drugs in prostate cancer > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoids-prostate-cancer-anti-tumor-drugs/ > **Published:** 2021-03-30T14:25:42-04:00 | **Last Modified / Clinically Audited:** 2026-09-05T08:07:42-04:00 > **Clinical Summary:** Explore cannabinoids prostate cancer as promising anti-tumor drugs targeting cancer and stromal cells in prostate cancer progression. --- ### Treatment with Cannabinoids as a Promising Approach for Impairing Fibroblast Activation and Prostate Cancer Progression ​In Summary Cannabinoids are lipids that can regulate multiple biological processes by interacting with cell-surface [cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/), namely CB1 and CB2. Noticeably, these receptors are up-regulated in malignant tissues compared to healthy tissues and a correlation between their higher expression and poorer disease prognosis is proven for many cancers. In the case of prostate cancer, both CB1 and CB2 have been identified as regulators of tumorous cells proliferation, invasion and migration to other organs (the process underlying metastasis). However, to date, it is widely accepted that cancer outcome does not only depend on the behavior of cancer cells, but also on the tumor microenvironment (TME) that nourish proliferation and support migrations of the cancer cells. In prostate cancer particularly, cancer associated fibroblasts (CAFs) is the most abundant stromal cells, playing an essential role during all stages of [disease progression](https://cedclinic.com/multiple-sclerosis-biomarkers-p21-protein-variations/), including metastasis. Patient-derived prostate CAFs also have higher CB1 and CB2 expression than normal fibroblasts (HPFs). Thus, it is crucial that cancer therapy targets all components of the TME. A growing body of evidence in the last few decades has supported cannabinoids’ ability to influence cancer progression in models of human cancers. Specifically in prostate cancer, cannabinoids exhibit anti-proliferative and anti-invasive effects of cancerous cells. Furthermore, a synthetic cannabinoid has recently also been demonstrated to impair activities of CAFs, preventing them from supplying nutrients for and supporting invasion of tumors. Because of these findings, which highlight that they can simultaneously attack cancer and stromal cells, cannabinoids are increasingly recognized as promising anti-cancer drugs, especially in prostate cancer patients. [More access here](https://cedclinic.com/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabidiol may enhance the effectiveness of immunotherapy in multiple myeloma](https://cedclinic.com/cannabidiol-may-enhance-the-effectiveness-of-immunotherapy-in-multiple-myeloma/) Discover how cannabidiol may improve immunotherapy outcomes in multiple myeloma, highlighting cannabinoid potential in cancer treatments. [Read More](https://cedclinic.com/cannabidiol-may-enhance-the-effectiveness-of-immunotherapy-in-multiple-myeloma/) [Cannabinoids in Combination with Conventional Breast Cancer Therapies: Mechanistic Insights and the Gap to Clinical Translation.](https://cedclinic.com/cannabinoid-anti-tumor-effects-breast-cancer/) Explore the synergistic effects of cannabinoids with breast cancer therapies and the challenges in clinical application. [Learn More](https://cedclinic.com/cannabinoid-anti-tumor-effects-breast-cancer/) [Anti-Invasion Effects of Cannabinoids on Breast Cancer Stem Cells](https://cedclinic.com/cannabinoids-breast-cancer-stem-cells-anti-invasion-effects/) Study the anti-invasion properties of cannabinoids on [breast cancer stem cells](https://cedclinic.com/cannabinoids-breast-cancer-stem-cells-anti-invasion-effects/) and their potential [therapeutic benefits](https://cedclinic.com/therapeutic-benefits-of-thc/). [Explore Article](https://cedclinic.com/cannabinoids-breast-cancer-stem-cells-anti-invasion-effects/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabinoids%20as%20promising%20anti-tumor%20drugs%20in%20prostate%20cancer&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-prostate-cancer-anti-tumor-drugs%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-prostate-cancer-anti-tumor-drugs%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabinoids%20as%20promising%20anti-tumor%20drugs%20in%20prostate%20cancer%20https%3A%2F%2Fcedclinic.com%2Fcannabinoids-prostate-cancer-anti-tumor-drugs%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).